FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)

Persistent ID (NDL): info:ndljp/pid/12361216

Material type: 博士論文

Author: 籏智, 幸政

Publisher: -

Publication date: 2022-09-21

Material Format: Digital

Capacity, size, etc.: -

Name of awarding university/degree: 香川大学,博士（医学）

View All

Notes on use at the National Diet Library

本資料は、掲載誌(URI)等のリンク先にある学位授与機関のWebサイトやCiNii Dissertationsから、本文を自由に閲覧できる場合があります。

Notes on use

Note (General)：: Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advance...

Search by Bookstore

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 博士論文
Title: FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)
Author/Editor: 籏智, 幸政
Author Heading: 籏智, 幸政
Publication Date: 2022-09-21
Publication Date (W3CDTF): 2022-09-21
Degree grantor/type: 香川大学
Date Granted: 2022-09-21
Date Granted (W3CDTF): 2022-09-21
Dissertation Number: 乙第299号
Degree Type: 博士（医学）
Conferring No. (Dissertation): 乙第299号
Text Language Code: eng
Alias of Author: Hatachi, Yukimasa
Subject Heading: FOLFIRINOX
pancreatic cancer
optimal dose
dose limiting toxicity
Target Audience: 一般
Note (General): Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.
Patients and methods: Patients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities.
Results: Patients given 180 mg of irinotecan and a 400 mg bolus of 5-fluorouracil (5-FU) showed a marked difference in outcome when compared to irinotecan 180 mg given without the 5-FU bolus, with the overall response rate being 28%, a survival time of 6.4 months and progression-free survival time of 4.5 months.
Conclusion: The optimum dose of FOLFIRINOX was a dosage combination of oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , l-leucovorin 400 mg/m 2 and 5-FU 2,400 mg/m 2 , administered as a continuous 46-h infusion.
DOI: info:doi/10.21873/cdp.10083
https://doi.org/info:doi/10.21873/cdp.10083
Persistent ID (NDL): info:ndljp/pid/12361216
https://dl.ndl.go.jp/pid/12361216
Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
https://dl.ndl.go.jp/collections/A00014
Acquisition Basis: 博士論文（自動収集）
Date Accepted (W3CDTF): 2022-11-07T16:56:35+09:00
Date Created (W3CDTF): 2022-10-18
Format (IMT): PDF
Access Restrictions: 国立国会図書館内限定公開
Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
Availability of remote photoduplication service: 可
Periodical Title (URI): https://kagawa-u.repo.nii.ac.jp/records/11466
Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション
https://dl.ndl.go.jp